BMY Bristol-Myers Squibb Company
Healthcare$58.03-2.40%ClosedMarket Cap: $118.50B
As of 2026-05-26
Valuation
P/E (TTM)
16.93
PEG
0.09
P/B
6.05
P/S
2.50
EV/EBITDA
11.35
DCF Value
$259.98
FCF Yield
9.8%
Div Yield
4.2%
Margins & Returns
Gross Margin
68.7%
Operating Margin
25.7%
Net Margin
15.0%
ROE
39.0%
ROA
8.4%
ROIC
13.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $11.49B | 70.2% | $3.27B | $2.68B | $— | $0.63 |
| Q4 null | $12.50B | 67.2% | $1.42B | $1.09B | $— | $0.62 |
| FY null | $48.19B | 67.6% | $12.70B | $7.05B | $— | $2.48 |
| Q3 null | $12.22B | 71.9% | $3.64B | $2.20B | $— | $0.62 |
| Q2 null | $12.27B | 65.8% | $4.12B | $1.31B | $— | $0.62 |
| Q1 null | $11.20B | 65.5% | $3.52B | $2.46B | $— | $0.62 |
| Q4 null | $12.34B | 60.2% | $2.53B | $72.0M | $— | $0.60 |
| FY null | $48.30B | 56.8% | $9.66B | $-8.95B | $— | $2.40 |
| Q3 null | $11.89B | 55.6% | $2.29B | $1.21B | $— | $0.60 |
| Q2 null | $12.20B | 55.7% | $2.58B | $1.68B | $— | $0.60 |
| Q1 null | $11.87B | 55.5% | $1.53B | $-11.91B | $— | $0.60 |
| Q4 2023 | $11.48B | 56.6% | $1.95B | $1.76B | $0.87 | $0.57 |